Moderna shares up 4.4% ahead of Phase 3 melanoma data release

Shares rose 4.40% to $227.61 ahead of Phase 3 melanoma data presentation at ESMO. Bank of America increased price target to $220 from $200, maintaining Neutral rating. Trial tested intismeran autogene plus Keytruda in 1,137 patients with stage IIB-IV melanoma. Jefferies estimates peak unadjusted sales for melanoma indication could top $3 billion. Stock rebounded from Friday's 10% drop from 52-week high of $242.29.

Goldman Sachs lifts Moderna price target to $137, keeps neutral rating

Goldman Sachs raised Moderna's price target to $137. The previous price target was set at $120. Analyst Salveen Richter maintained a Neutral rating. No change was made to the overall investment stance.

Moderna shares rise 3% after Power Inflow signal triggers reversal

Moderna shares rose 3.38% from the signal trigger price of $186.46. Stock reversed an early 5% decline following a Power Inflow alert. Post-signal high reached $192.76 by 2:45 pm EST on September 30. TradePulse signal indicated shift in institutional and retail buying interest.

Moderna shares fall 8% as company appoints new chief operating officer

Moderna shares fell 8.23% to $186.70 on Wednesday. Juan Andres appointed Chief Operating Officer effective October 5. Company expands vaccine franchise to five approved products. Positive Phase 3 data reported for intismeran autogene with Merck.

Moderna sets fresh 52-week high of $208.90 on ESMO momentum

Moderna shares hit a fresh 52-week high of $208.90 on Tuesday, clearing the prior record of $202.67 set after Friday's breakout. The rally is driven by ESMO Congress acceptance of three abstracts on intismeran autogene, including a Phase 3 melanoma data presentation pairing the drug with Keytruda. The INTerpath-001 trial enrolled 1,137 patients and met its primary recurrence-free-survival endpoint, marking the first Phase 3 success for a personalized neoantigen vaccine. Moderna's 12-month gain stands at 655.41%, with an RSI of 75.12, while the average analyst price target remains at $91 with a Hold consensus. The stock is outperforming the healthcare sector by 2.15 percentage points on the day, even as healthcare ranks ninth among 11 S&P sectors.

Moderna stock falls 3% after 170% surge and $2.6 billion note issuance

Moderna stock fell 3.07% to $149.54 on Wednesday after a 170% monthly surge. Company closed a $2.6 billion convertible note offering due in 2032. Phase 3 melanoma trial with Merck met primary endpoints for survival metrics. FDA approved mFLUSIVA flu vaccine and updated COVID-19 formulations.